Side-by-side scientific comparisons of research peptides. Mechanism of action, molecular properties, receptor targets, and key research citations.
This guide provides structured comparisons of commonly researched peptide pairs. Each section includes a property-by-property comparison table, key mechanistic differences, and a research summary with citations. For definitions of technical terms used throughout this page, see our peptide glossary.
BPC-157 and TB-500 are two of the most widely studied peptides in tissue repair research. While both are investigated for their regenerative properties, they differ substantially in origin, mechanism, and primary research applications.
| Property | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Category | Gastric pentadecapeptide (body protection compound) | Thymosin beta-4 fragment (43-amino-acid peptide) |
| Mechanism of Action | Modulates nitric oxide (NO) system, upregulates growth factor expression (EGF, NGF), promotes angiogenesis | Sequesters G-actin monomers, promotes cell migration and differentiation, upregulates actin polymerization |
| Molecular Weight | ~1,419 Da (15 amino acids) | ~4,963 Da (43 amino acids) |
| Origin | Derived from human gastric juice protein BPC | Naturally occurring peptide isolated from thymus gland |
| Primary Research Focus | Gastrointestinal tissue, tendon and ligament healing, neuroprotection | Cardiac tissue repair, wound healing, anti-inflammatory activity |
| Receptor Target | No single identified receptor; modulates FAK-paxillin and JAK-2/STAT-3 pathways | Interacts with actin cytoskeleton; no traditional receptor-ligand binding |
| Half-Life | Stable in gastric juice (>24 hours); systemic half-life under investigation | Estimated 2-3 hours in circulation |
| Key Research Citations | Sikiric et al. (2018), J Physiol Pharmacol; Seiwerth et al. (2014), Curr Pharm Des | Goldstein et al. (2012), Expert Opin Biol Ther; Sosne et al. (2010), Ann N Y Acad Sci |
BPC-157 and TB-500 represent complementary approaches to tissue repair research. BPC-157 is distinguished by its gastric origin and multi-pathway mechanism involving nitric oxide and growth factor modulation, while TB-500 operates through actin cytoskeletal regulation. Researchers frequently study both peptides in combination protocols to evaluate potential synergistic effects across musculoskeletal, cardiovascular, and soft tissue models.
Semaglutide and tirzepatide are both investigated for their effects on glucose metabolism and body composition. The critical distinction is that semaglutide is a single-target GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Category | GLP-1 receptor agonist (single agonist) | GIP/GLP-1 dual receptor agonist (twincretin) |
| Mechanism of Action | Mimics endogenous GLP-1; activates GLP-1 receptor to stimulate insulin secretion, suppress glucagon, slow gastric emptying | Activates both GIP and GLP-1 receptors simultaneously; enhances insulin sensitivity through dual incretin pathways |
| Molecular Weight | ~4,113 Da | ~4,810 Da |
| Primary Research Focus | Type 2 diabetes, obesity, cardiovascular risk reduction, NASH/MAFLD | Type 2 diabetes, obesity, cardiovascular outcomes, combined metabolic syndrome |
| Receptor Target | GLP-1 receptor (selective) | GIP receptor (primary) + GLP-1 receptor (secondary) |
| Half-Life | ~7 days (albumin binding via C-18 fatty diacid) | ~5 days (C-20 fatty diacid moiety enables albumin binding) |
| Key Research Citations | Wilding et al. (2021), STEP trials, NEJM; Marso et al. (2016), SUSTAIN-6, NEJM | Jastreboff et al. (2022), SURMOUNT-1, NEJM; Frias et al. (2021), SURPASS trials, NEJM |
The fundamental difference between semaglutide and tirzepatide lies in receptor pharmacology. Semaglutide is a selective GLP-1 receptor agonist with extensive clinical evidence across metabolic and cardiovascular endpoints. Tirzepatide introduces a dual agonist mechanism targeting both GIP and GLP-1 receptors, which may account for its enhanced metabolic effects observed in comparative studies. Both compounds have extended half-lives through albumin-binding fatty acid modifications, enabling once-weekly research protocols.
Ipamorelin and CJC-1295 are both studied for their growth hormone (GH) releasing properties, but they operate through different receptor systems. Ipamorelin is a ghrelin mimetic (GHSR agonist), while CJC-1295 is a growth hormone-releasing hormone (GHRH) analog.
| Property | Ipamorelin | CJC-1295 |
|---|---|---|
| Category | Growth hormone secretagogue (ghrelin mimetic) | GHRH analog (modified GRF 1-29) |
| Mechanism of Action | Selective agonist of the growth hormone secretagogue receptor (GHSR/ghrelin receptor); stimulates pulsatile GH release | Binds GHRH receptor on somatotroph cells; amplifies natural GH-releasing hormone signaling |
| Molecular Weight | ~711 Da (5 amino acids) | ~3,367 Da (29 amino acids, with DAC variant ~3,647 Da) |
| Primary Research Focus | GH pulse amplitude, bone mineral density, body composition | Sustained GH elevation, IGF-1 levels, anti-aging research models |
| Receptor Target | GHSR-1a (ghrelin receptor) — highly selective, minimal effect on cortisol, ACTH, or prolactin | GHRH receptor on anterior pituitary somatotrophs |
| Half-Life | ~2 hours | ~30 minutes (mod GRF 1-29); ~8 days (CJC-1295 with DAC) |
| Key Research Citations | Raun et al. (1998), Eur J Endocrinol; Anderson et al. (2001), J Clin Endocrinol Metab | Teichman et al. (2006), J Clin Endocrinol Metab; Ionescu & Bhatt (2004), Horm Res |
Ipamorelin and CJC-1295 target different nodes of the growth hormone axis. Ipamorelin mimics ghrelin to stimulate pulsatile GH release with high selectivity and minimal off-target hormonal effects. CJC-1295 amplifies GHRH signaling, and in its DAC-modified form, provides sustained GH elevation over days rather than hours. The two peptides are often studied together in combination protocols because their distinct mechanisms may produce complementary effects on GH secretion patterns.
PT-141 (bremelanotide) and Melanotan II are both melanocortin receptor agonists derived from the alpha-melanocyte-stimulating hormone (alpha-MSH) scaffold. However, they differ in receptor selectivity and the breadth of their studied effects.
| Property | PT-141 (Bremelanotide) | Melanotan II |
|---|---|---|
| Category | Melanocortin receptor agonist (selective MC3R/MC4R) | Non-selective melanocortin receptor agonist (MC1R-MC5R) |
| Mechanism of Action | Cyclic heptapeptide; preferentially activates MC3R and MC4R in the central nervous system, modulating hypothalamic signaling | Cyclic lactam analog of alpha-MSH; activates multiple melanocortin receptors including MC1R (pigmentation) and MC4R (central effects) |
| Molecular Weight | ~1,025 Da (7 amino acids, cyclic) | ~1,024 Da (7 amino acids, cyclic lactam) |
| Primary Research Focus | Sexual dysfunction research, central nervous system melanocortin pathways | Skin pigmentation, photoprotection, appetite regulation research |
| Receptor Target | MC3R and MC4R (selective) | MC1R, MC3R, MC4R, MC5R (non-selective) |
| Half-Life | ~2.5 hours | ~1-2 hours (estimated) |
| Key Research Citations | Molinoff et al. (2003), Ann N Y Acad Sci; Kingsberg et al. (2019), Obstet Gynecol | Dorr et al. (1996), Life Sci; Hadley et al. (2005), Peptides |
PT-141 and Melanotan II share a common structural origin in the alpha-MSH scaffold, but represent different pharmacological strategies. Melanotan II is a broad-spectrum melanocortin agonist studied for pigmentation and multiple CNS effects. PT-141 was engineered from Melanotan II through structural modifications that shifted receptor selectivity toward MC3R/MC4R while eliminating significant MC1R activation, making it a more targeted tool for melanocortin CNS pathway research.
NAD+ (nicotinamide adenine dinucleotide) and NMN (nicotinamide mononucleotide) are both central to cellular energy metabolism and aging research. NAD+ is the active coenzyme itself, while NMN is its direct biosynthetic precursor.
| Property | NAD+ | NMN (Nicotinamide Mononucleotide) |
|---|---|---|
| Category | Coenzyme (active form) | NAD+ precursor (biosynthetic intermediate) |
| Mechanism of Action | Functions as electron carrier in redox reactions (glycolysis, TCA cycle, oxidative phosphorylation); substrate for sirtuins, PARPs, and CD38 | Converted to NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT); bypasses the rate-limiting NAMPT step in salvage pathway |
| Molecular Weight | 663.4 Da | 334.2 Da |
| Primary Research Focus | Cellular energetics, DNA repair (PARP activity), sirtuin activation, mitochondrial function | NAD+ repletion, age-related NAD+ decline, metabolic function, longevity research |
| Bioavailability | Limited direct cellular uptake due to size and charge; relies on extracellular degradation and precursor transport | Transported via Slc12a8 transporter (identified in murine models); smaller molecular weight may facilitate absorption |
| Half-Life | 1-2 hours in circulation (rapidly consumed by NAD+-dependent enzymes) | 2-3 minutes in plasma (rapidly converted to NAD+ or other metabolites) |
| Key Research Citations | Verdin (2015), Science; Canto et al. (2015), Cell Metab; Yoshino et al. (2018), Cell Metab | Mills et al. (2016), Cell Metab; Yoshino et al. (2011), Science; Grozio et al. (2019), Nat Metab |
NAD+ and NMN occupy different positions in the same metabolic pathway. NAD+ is the functional coenzyme essential for cellular energy production, DNA repair, and epigenetic regulation through sirtuin enzymes. NMN is its direct biosynthetic precursor, investigated as a strategy to elevate intracellular NAD+ levels. The key research question is whether supplying the precursor (NMN) or the end product (NAD+) more effectively raises tissue NAD+ concentrations, with current evidence suggesting that NMN may have advantages in oral bioavailability due to its smaller molecular size and identified transport mechanisms.
BPC-157 is a synthetic pentadecapeptide derived from gastric juice that modulates nitric oxide pathways and growth factor expression, primarily studied for gastrointestinal and tendon repair. TB-500 is a fragment of thymosin beta-4 that regulates actin polymerization and cell migration, primarily studied for cardiac tissue regeneration and wound healing. They differ in origin, molecular weight (1,419 Da vs 4,963 Da), and mechanism of action.
Semaglutide is a selective GLP-1 receptor agonist with a ~7-day half-life, while tirzepatide is a dual GIP/GLP-1 receptor agonist with a ~5-day half-life. The key distinction is that tirzepatide activates two incretin receptors simultaneously, which may account for the greater metabolic effects observed in head-to-head clinical trials such as SURPASS-2.
Yes, ipamorelin and CJC-1295 (mod GRF 1-29) are frequently studied in combination because they target different receptor systems. Ipamorelin activates the ghrelin receptor (GHSR-1a) for pulsatile growth hormone release, while CJC-1295 amplifies GHRH receptor signaling. Their complementary mechanisms may produce synergistic effects on GH secretion patterns.
PT-141 (bremelanotide) is a selective MC3R/MC4R agonist engineered from Melanotan II to target central nervous system melanocortin pathways without significant pigmentation effects. Melanotan II is a non-selective melanocortin agonist that activates MC1R through MC5R, producing both pigmentation and CNS effects. PT-141 was specifically designed to remove the MC1R-mediated melanogenesis activity of Melanotan II.
NAD+ is the active coenzyme used by over 500 enzymes including sirtuins and PARPs, but faces bioavailability challenges due to its larger molecular weight (663 Da). NMN is its direct precursor (334 Da) and may be more efficiently absorbed via the Slc12a8 transporter. Current research suggests NMN supplementation effectively raises tissue NAD+ levels, but the optimal approach depends on the specific research model and endpoints being studied.
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.